MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance

MicroRNAs (miRNAs, or miRs) are single-strand short non-coding RNAs with a pivotal role in the regulation of physiological- or disease-associated cellular processes. They bind to target miRs modulating gene expression at post-transcriptional levels. Here, we present an overview of miRs deregulation in the pathogenesis of multiple myeloma (MM), and discuss the potential use of miRs/nanocarriers association in clinic. Since miRs can act as oncogenes or tumor suppressors, strategies based on their inhibition and/or replacement represent the new opportunities in cancer therapy. The miRs delivery systems include liposomes, polymers, and exosomes that increase their physical stability and prevent nuclease degradation. Phase I/II clinical trials support the importance of miRs as an innovative therapeutic approach in nanomedicine to prevent cancer progression and drug resistance. Results in clinical practice are promising.

[1]  K. Kelnar,et al.  Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours , 2020, British Journal of Cancer.

[2]  Sundeep Kumar,et al.  Identification and evolutionary analysis of polycistronic miRNA clusters in domesticated and wild wheat. , 2020, Genomics.

[3]  M. Egeblad,et al.  Communication in tiny packages: Exosomes as means of tumor-stroma communication. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[4]  H. Handa,et al.  The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma , 2019, Cancers.

[5]  K. Ohyashiki,et al.  Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. , 2019, Blood advances.

[6]  H. Einsele,et al.  High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment , 2019, Journal of clinical medicine.

[7]  J. Kocerha,et al.  The Potential for microRNA Therapeutics and Clinical Research , 2019, Front. Genet..

[8]  B. Nico,et al.  Bone marrow fibroblasts overexpress miR‐27b and miR‐214 in step with multiple myeloma progression, dependent on tumour cell‐derived exosomes , 2019, The Journal of pathology.

[9]  S. Bhattacharjee,et al.  Combination therapy to checkmate Glioblastoma: clinical challenges and advances , 2018, Clinical and Translational Medicine.

[10]  C. Peng,et al.  Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation , 2018, Front. Endocrinol..

[11]  Jing Peng,et al.  The expression and role of miR-181a in multiple myeloma , 2018, Medicine.

[12]  Behzad Baradaran,et al.  Treating cancer with microRNA replacement therapy: A literature review , 2018, Journal of cellular physiology.

[13]  Guoan Chen,et al.  The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. , 2018, Oncology letters.

[14]  Carla Oliveira,et al.  Anti-miRNA oligonucleotides: A comprehensive guide for design , 2018, RNA biology.

[15]  Xi Luo,et al.  The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma , 2018, Oncology letters.

[16]  Saife Niaz The AGO proteins: an overview , 2018, Biological chemistry.

[17]  G. Reid,et al.  Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". , 2018, Translational lung cancer research.

[18]  P. Tassone,et al.  Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment , 2017, Scientific Reports.

[19]  N. Munshi,et al.  MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells , 2017, Leukemia.

[20]  Lin Xm,et al.  MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway. , 2017 .

[21]  S. Baldari,et al.  Exosomes and other extracellular vesicles-mediated microRNA delivery for cancer therapy , 2017 .

[22]  T. Whiteside,et al.  Response Commentary: Exosomes vs microvesicles in hematological malignancies , 2017, Leukemia.

[23]  I. Fernandez-Piñeiro,et al.  Nanocarriers for microRNA delivery in cancer medicine. , 2017, Biotechnology advances.

[24]  J. Fei,et al.  Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells , 2017, Functional & Integrative Genomics.

[25]  O. Elemento,et al.  Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell , 2017, Nucleic acids research.

[26]  L. Trippa,et al.  Prognostic role of circulating exosomal miRNAs in multiple myeloma. , 2017, Blood.

[27]  A. Brenner,et al.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.

[28]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[29]  S. Khan,et al.  miRNA nanotherapeutics for cancer. , 2017, Drug discovery today.

[30]  John T. Powers,et al.  The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma , 2016, Leukemia.

[31]  B. Nico,et al.  Microenvironment drug resistance in multiple myeloma: emerging new players , 2016, Oncotarget.

[32]  X. Leleu,et al.  Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. , 2016, Cancer letters.

[33]  F. Slack,et al.  OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. , 2016, Cancer research.

[34]  Jian Li,et al.  MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT , 2016, Journal of Biological Research-Thessaloniki.

[35]  Keunchil Park,et al.  MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy. , 2016 .

[36]  N. Pavlakis,et al.  Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. , 2016, Epigenomics.

[37]  Meng Chen,et al.  Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma , 2016, Oncotarget.

[38]  N. Munshi,et al.  Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma , 2016, Molecular Cancer Therapeutics.

[39]  Saurabh Singh,et al.  Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. , 2016, Therapeutic delivery.

[40]  Jie Tian,et al.  Effect of surface properties on liposomal siRNA delivery. , 2016, Biomaterials.

[41]  Massimo Fresta,et al.  Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma , 2015, Scientific Reports.

[42]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[43]  N. Munshi,et al.  A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells , 2015, Clinical Cancer Research.

[44]  Chun-mei Wang,et al.  MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. , 2015, Oncology letters.

[45]  Jian-jun Zhao,et al.  Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. , 2015, Cancer research.

[46]  Won Jong Kim,et al.  Simultaneous Drug and Gene Delivery from the Biodegradable Poly(ε-caprolactone) Nanofibers for the Treatment of Liver Cancer. , 2015, Journal of nanoscience and nanotechnology.

[47]  K. Anderson,et al.  Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo , 2015, Leukemia.

[48]  J. Willmann,et al.  Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Wei Huang,et al.  Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment , 2015, Acta pharmaceutica Sinica. B.

[50]  P. Tassone,et al.  A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells , 2014, Journal of cellular physiology.

[51]  Tao Gong,et al.  Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[52]  R. Tekade,et al.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[53]  T. Jiang,et al.  MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. , 2014, Neuro-oncology.

[54]  K. Anderson,et al.  MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib , 2014, Leukemia.

[55]  Mark Ibberson,et al.  Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. , 2014, Cell reports.

[56]  M. Bushell,et al.  The complexity of miRNA-mediated repression , 2014, Cell Death and Differentiation.

[57]  P. Tassone,et al.  Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.

[58]  L. Pfeffer,et al.  MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers , 2014, Breast Cancer Research.

[59]  Lin He,et al.  miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2 , 2014, Nature.

[60]  Silvia Catuogno,et al.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  Giuseppina Turturici,et al.  Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. , 2014, American journal of physiology. Cell physiology.

[62]  E. Anaissie,et al.  MicroRNA theragnostics for the clinical management of multiple myeloma , 2014, Leukemia.

[63]  F. Camargo,et al.  Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer , 2014, Cell.

[64]  M. Cannataro,et al.  In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma , 2014, PloS one.

[65]  Christopher J. Cheng,et al.  Sustained delivery of proangiogenic microRNA‐132 by nanoparticle transfection improves endothelial cell transplantation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  L. J. Lee,et al.  Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[67]  Yu Zhang,et al.  Progress in microRNA delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[68]  B. Moudgil,et al.  Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer , 2013, International journal of nanomedicine.

[69]  C. Cho,et al.  Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics , 2013, Expert opinion on drug delivery.

[70]  Michael Chopp,et al.  Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. , 2013, Cancer letters.

[71]  P. Tassone,et al.  miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease , 2013, Journal of cellular physiology.

[72]  L. J. Lee,et al.  Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer , 2013, Molecular therapy. Nucleic acids.

[73]  D. Scadden,et al.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. , 2013, The Journal of clinical investigation.

[74]  N. Munshi,et al.  Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.

[75]  Yu Hu,et al.  miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. , 2013, Carcinogenesis.

[76]  N. Munshi,et al.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.

[77]  M. Negrini,et al.  DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma , 2012, Oncotarget.

[78]  P. Tassone,et al.  MicroRNAs in the pathobiology of multiple myeloma. , 2012, Current cancer drug targets.

[79]  P. Tassone,et al.  Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma , 2012, Current cancer drug targets.

[80]  J. Sheng,et al.  Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. , 2012, Molecular pharmaceutics.

[81]  Christopher J. Cheng,et al.  Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma , 2012, Proceedings of the National Academy of Sciences.

[82]  Nahum Sonenberg,et al.  The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC , 2012, Nature Structural &Molecular Biology.

[83]  E. Kimura,et al.  MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer , 2012, Oncogene.

[84]  V. Palanisamy,et al.  Horizontal transfer of RNAs: exosomes as mediators of intercellular communication , 2012, Wiley interdisciplinary reviews. RNA.

[85]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[86]  L. Benetatos,et al.  Deregulated microRNAs in multiple myeloma , 2012, Cancer.

[87]  A. Bader,et al.  Developing therapeutic microRNAs for cancer , 2011, Gene Therapy.

[88]  Yuefeng Yang,et al.  Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. , 2011, Biochemical and biophysical research communications.

[89]  Jianyong Li,et al.  miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. , 2011, Cancer letters.

[90]  Huimin Wang,et al.  Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation , 2011, Leukemia & lymphoma.

[91]  R. Hartmann,et al.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. , 2011, Cancer research.

[92]  Bo Yu,et al.  MicroRNA delivery by cationic lipoplexes for lung cancer therapy. , 2011, Molecular pharmaceutics.

[93]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[94]  R. Carrasco,et al.  Pathogenesis of myeloma. , 2011, Annual review of pathology.

[95]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[96]  Kwan Yeung Wong,et al.  Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies , 2010, PloS one.

[97]  N. Heerema,et al.  MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines , 2010, Acta Haematologica.

[98]  Ji Wan,et al.  Structure and activity of putative intronic miRNA promoters. , 2010, RNA.

[99]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[100]  C. Croce Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[101]  Charles P. Lin,et al.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. , 2009, Blood.

[102]  C. Croce,et al.  SnapShot: MicroRNAs in Cancer , 2009, Cell.

[103]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[104]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[105]  F. Slack,et al.  let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.

[106]  Dong Wei,et al.  Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer , 2008, Molecular Therapy.

[107]  D. Iliopoulos,et al.  E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. , 2008, Cancer cell.

[108]  Jörg Hackermüller,et al.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.

[109]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[110]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[111]  Zhiyuan Hu,et al.  A novel PEGylation of chitosan nanoparticles for gene delivery , 2007, Biotechnology and applied biochemistry.

[112]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[113]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[114]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[115]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[116]  J. Hecker,et al.  Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. , 2003, Human gene therapy.

[117]  V. Kim,et al.  MicroRNA maturation: stepwise processing and subcellular localization , 2002, The EMBO journal.

[118]  K. Anwer,et al.  Cationic lipid-based delivery system for systemic cancer gene therapy , 2000, Cancer Gene Therapy.

[119]  T. Bettinger,et al.  Chitosan-Based Vector/DNA Complexes for Gene Delivery: Biophysical Characteristics and Transfection Ability , 1998, Pharmaceutical Research.

[120]  M. Scheideler,et al.  Lipid Nanocarriers for microRNA Delivery. , 2019, Chemistry and physics of lipids.

[121]  Y. Zhang,et al.  MicroRNA-92 regulates vascular smooth muscle cell function by targeting KLF4 during vascular restenosis and injury. , 2019, International journal of clinical and experimental pathology.

[122]  X-M Li,et al.  MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway. , 2017, European review for medical and pharmacological sciences.

[123]  Hyundong Yoo,et al.  Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery , 2014, Archives of Pharmacal Research.

[124]  R. Mahato,et al.  miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. , 2015, Advanced drug delivery reviews.

[125]  Leaf Huang,et al.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies. , 2015, Advanced drug delivery reviews.

[126]  Zhiguo Wang The guideline of the design and validation of MiRNA mimics. , 2011, Methods in molecular biology.

[127]  J. Costello,et al.  Epigenetic inactivation of the miR-34a in hematological malignancies. , 2010, Carcinogenesis.